Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma - Scorecard - MDSpire

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • By

  • Laura B. Oswald

  • Xiaoyin Li

  • Lisa M. Gudenkauf

  • Gabe De Avila

  • David Scheiber-Camoretti

  • Brent J. Small

  • Brian D. Gonzalez

  • Aasha I. Hoogland

  • Oanh Nguyen

  • Yvelise Rodriguez

  • Sylvia L. Crowder

  • Nathan H. Parker

  • Tiffany L. Carson

  • Christine E. Vinci

  • Rachid C. Baz

  • Kenneth H. Shain

  • Brandon Blue

  • Ariel Grajales-Cruz

  • Kristy Matte

  • Brandon Kale

  • David Kaldas

  • Fabiana Perna

  • Melissa Alsina

  • Ciara L. Freeman

  • Omar Castaneda Puglianini

  • Taiga Nishihori

  • Hien Liu

  • Frederick L. Locke

  • Heather S. L. Jim

  • Lauren C. Peres

  • Doris K. Hansen

  • May 11, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Patient-Reported Outcomes Following Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy in Multiple Myeloma Patients

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingMoffitt Cancer Center, an NCI-designated comprehensive cancer center involved in the study.

Key Highlights

  • Add specific statistics or data points to substantiate claims about PRO improvements.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Specify the frequency and methods for PRO assessments beyond the initial timeline.

      Risks

        Patient & Prescribing Data

        Cite the studies or trials that provide the response rates for ide-cel and cilta-cel.

        Clinical Best Practices

        • suggestions

        References

        Original Source(s)

        Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

        • by Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Gabe De Avila, David Scheiber-Camoretti, Brent J. Small, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Sylvia L. Crowder, Nathan H. Parker, Tiffany L. Carson, Christine E. Vinci, Rachid C. Baz, Kenneth H. Shain, Brandon Blue, Ariel Grajales-Cruz, Kristy Matte, Brandon Kale, David Kaldas, Fabiana Perna, Melissa Alsina, Ciara L. Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick L. Locke, Heather S. L. Jim, Lauren C. Peres, Doris K. Hansen

        • May 11, 2026

        Related Content

        Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

        Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

        Synthetic short RNA in cancer